A growing body of research suggests that combining montelukast and bilastine may improve symptom control for people with allergic rhinitis while maintaining a favorable safety profile
Boston, Massachusetts, 30 July 2026 – Allergic rhinitis, commonly known as hay fever, affects millions of people worldwide and often causes sneezing, a runny nose, nasal congestion, and itchy eyes. While antihistamines remain a standard treatment, researchers continue to explore combination therapies that may provide better relief for patients whose symptoms are not fully controlled with a single medication.
A recent narrative review highlights the potential benefits of combining montelukast, a leukotriene receptor antagonist, with bilastine, a second-generation antihistamine. The review suggests that the two medicines work through different biological pathways, allowing them to target multiple causes of allergic inflammation at the same time. This complementary approach may help reduce both nasal and non-nasal symptoms more effectively than treating only one pathway.
Bilastine is widely recognized for relieving allergy symptoms while causing minimal drowsiness in most patients. Montelukast, on the other hand, helps block inflammatory chemicals known as leukotrienes that contribute to nasal swelling and congestion. Together, these medicines may offer broader symptom control, particularly for people with moderate to severe allergic rhinitis.
The review also points to clinical studies showing that the fixed-dose combination of montelukast and bilastine improved overall symptom scores and was generally well tolerated. Researchers noted that the treatment demonstrated comparable or favorable results when evaluated against other commonly prescribed combination therapies, offering another option for physicians managing persistent allergy symptoms.
Beyond symptom relief, effective allergy management can improve sleep quality, workplace productivity, school performance, and overall quality of life. Since allergic rhinitis often affects daily routines, treatments that control symptoms throughout the day may help patients maintain normal activities with fewer interruptions.
Researchers also emphasize that treatment should be tailored to each patient’s symptoms, medical history, and overall health. While combination therapy may benefit many individuals, healthcare professionals should determine the most appropriate treatment plan based on individual needs and current clinical guidelines.
As research into allergy care continues to evolve, combination therapies are gaining attention as a way to improve patient outcomes. The growing evidence surrounding montelukast and bilastine reflects the broader trend toward personalized treatment strategies that focus on both effectiveness and patient comfort.
